A comparison of approved indications between regulatory agencies

Please use this identifier to cite or link to this item: https://www.um.edu.mt/library/oar/handle/123456789/50747

Title:	A comparison of approved indications between regulatory agencies
Authors:	Camilleri, Matthew Borg, John-Joseph Sammut Bartolo, Nicolette Serracino-Inglott, Anthony
Keywords:	Drug evaluation -- Standards Administrative agencies -- Medical care European Agency for the Evaluation of Medicinal Products Drugs -- Law and legislation -- United States Drugs -- Law and legislation -- Europe Cardiovascular Agents
Issue Date:	2018-10
Publisher:	University of Malta. Department of Pharmacy
Citation:	Camilleri, M., Borg, J. J., Sammut Bartolo, N., & Serracino-Inglott, A. (2018, October). A comparison of approved indications between regulatory agencies. Poster session presented at the ACCP Global Conference on Clinical Pharmacy, Seattle, Washington, USA.
Abstract:	A poster presentation regarding a comparison of approved indications between regulatory agencies. Introduction: Medicinal products are allowed on the market following approval by autonomous regulatory agencies which are tasked with their evaluation. Differences in evaluation practices during the registration of medicinal products are found in Europe and the United States of America which may lead to discrepancies in clinical guidelines, pricing policies, and drug use. Aims: To compare the differences in the indications of medicinal products authorised by the European Medicines Agency (EMA) and the US Food & Drug Administration using new molecular entity cardiology-related medicinal products as examples.
URI:	https://www.um.edu.mt/library/oar/handle/123456789/50747
Appears in Collections:	Scholarly Works - FacM&SPha

Files in This Item:

File	Description	Size	Format
A_comparison_of_approved_indications_between_regulatory_agencies_2018.pdf		335.63 kB	Adobe PDF	View/Open

Show full item record Statistics